Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Evaluation of GABAergic Transmission Modulation as a Novel Functional Target for Management of Multiple Sclerosis: Exploring Inhibitory Effect of GABA on Glutamate-Mediated Excitotoxicity.
Prevalence of Lhermitte's sign in multiple sclerosis versus neuromyelitis optica.
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters.
The epidemiology and pathophysiology of neurogenic bladder.
Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients.
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.
Endotoxin-induced systemic inflammation activates microglia: [(11)C]PBR28 positron emission tomography in nonhuman primates.
Myelin-derived lipids modulate macrophage activity by liver x receptor activation.
[Importance and treatment of spasticity in multiple sclerosis : Results of the MOVE 1 study].
Low body weight linked to PML risk with natalizumab in MS
Perivenular brain lesions in a primate multiple sclerosis model at 7-tesla magnetic resonance imaging.
Fingolimod protects against neonatal white matter damage and long-term cognitive deficits caused by hyperoxia.
Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
Exploring the potential of public proteomics data.
The role of angiogenesis in the pathology of multiple sclerosis.
Multiple Sclerosis and CCSVI: A Population-Based Case Control Study.
Transanal irrigation for bowel symptoms in patients with multiple sclerosis.
Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab.
Detecting clinically-relevant changes in progressive multiple sclerosis.
Clinical trials to clinical use: using vision as a model for multiple sclerosis and beyond.
Should we feel free to use loco-regional anesthesia in multiple sclerosis?
Imaging resting state brain function in multiple sclerosis.
Exercise in the community for people with multiple sclerosis -- a follow-up of people with minimal gait impairment.
Mitochondrial Complex Enzyme Activities and Cytochrome c Expression Changes in Multiple Sclerosis.
Pages
« first
‹ previous
…
315
316
317
318
319
320
321
322
323
…
next ›
last »